Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ARQ-252 cream 0.3%, ARQ-252 0.3%, ARQ-252 cream 0.1%, ARQ-252 0.1%
ARQ-252 · 1 trial · 1 indication
The number of Cohort 1 participants with an AE is reported. An AE is any untoward or unfavorable medical occurrence in a human participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to participation in the research.
The number of Cohort 1 participants with AEs coded as application site events is reported.
The number of Cohort 1 participants with an SAE is reported. An SAE is any AE that results in death, is life-threatening (places the subject at immediate risk of death from the event as it occurred), requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is any other adverse event that, based upon appropriate medical judgment, may jeopardize the subject's health.
The number of Cohort 1 participants with a significant change in hematology is reported.
The number of Cohort 1 participants with a significant change in chemistry is reported.
The IGA is 5-point scale assessing the severity of hand eczema; scores range from 0 ('completely clear') to 4 ('severe'), with higher scores indicating greater severity. The number of participants with an IGA score of 'clear' or 'almost clear' at Week 12 is presented.
| Arm | Type | Description |
|---|---|---|
| ARQ-252 cream 0.3% QD (once daily) | ACTIVE_COMPARATOR | Active Comparator |
| ARQ-252 cream 0.3% BID (twice daily) | ACTIVE_COMPARATOR | Active Comparator |
| ARQ-252 cream 0.1% QD (once daily) | ACTIVE_COMPARATOR | Active Comparator |
| Vehicle cream BID (twice daily) | PLACEBO_COMPARATOR | Placebo Comparator |
| Vehicle cream QD (once daily) | PLACEBO_COMPARATOR | Placebo Comparator |
| Name | Type | Description |
|---|---|---|
| ARQ-252 cream 0.3% | DRUG | ARQ-252 cream 0.3% |
| ARQ-252 cream 0.1% | DRUG | ARQ-252 cream 0.1% |
| ARQ-252 Vehicle Cream | DRUG | ARQ-252 Vehicle Cream |
Inclusion Criteria * Participants legally competent to sign and give informed consent. * Males and females 18 years of age and older (inclusive) at the time of consent. * Clinical diagnosis of chronic hand eczema, defined as hand eczema persistent for more than 3 months, or returned twice or more w...
ARQ-252 is an investigational topical small molecule developed by Arcutis Biotherapeutics for chronic hand eczema, a persistent inflammatory skin condition. It is formulated as a cream and has been studied in a Phase 1 clinical trial. ARQ-252 is not approved for commercial use and remains in clinical development.
ARQ-252 is being developed to treat chronic hand eczema, an inflammatory skin condition affecting the hands. It is a topical cream applied to the skin. The only completed clinical trial of ARQ-252 enrolled 230 adults with chronic hand eczema across the United States, Australia, and Canada.
ARQ-252 targets JAK1, a kinase enzyme involved in inflammatory signaling. By inhibiting JAK1, the topical cream is designed to reduce the inflammatory response in the skin. JAK1 inhibition is the mechanism under investigation for treating chronic hand eczema.
ARQ-252 is developed by Arcutis Biotherapeutics, Inc., a dermatology-focused biopharmaceutical company that trades under the ticker ARQT. Arcutis is responsible for the clinical development of the ARQ-252 cream formulations studied in chronic hand eczema.
ARQ-252 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The Phase 1 program for ARQ-252 has been completed, and the drug remains in clinical development for chronic hand eczema.
ARQ-252 has been studied in one completed Phase 1 trial, NCT04378569, titled Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema. The randomized, double-blind, placebo-controlled trial enrolled 230 adults aged 18 and older in the United States, Australia, and Canada.
Yes. ARQ-252 cream 0.3%, ARQ-252 0.3%, ARQ-252 cream 0.1%, and ARQ-252 0.1% are alternative names for ARQ-252, referring to different cream concentrations of the same investigational topical JAK1 inhibitor being developed by Arcutis Biotherapeutics for chronic hand eczema.